Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.54M Sell
35,969
-351
-1% -$15.1K 0.22% 81
2025
Q4
$1.59M Buy
36,320
+923
+3% +$38.2K 0.21% 89
2025
Q3
$1.46M Buy
35,397
+305
+0.9% +$12.3K 0.19% 86
2025
Q2
$1.55M Buy
+35,092
New +$1.4M 0.21% 83
2022
Q4
Sell
-46,590
Closed -$783K 153
2022
Q3
$783K Buy
46,590
+3,057
+7% +$59.1K 0.17% 95
2022
Q2
$958K Buy
+43,533
New +$897K 0.2% 84
2019
Q2
Sell
-23,310
Closed -$555K 113
2019
Q1
$555K Buy
+23,310
New +$532K 0.2% 68

Other funds holding EXEL

CIM LLC's EXEL Position: Q1 2026 in Review

CIM LLC reduced its Exelixis (EXEL) stake by 0.97% in Q1 2026, selling an estimated $15.1K and leaving 35,969 shares worth $1.54M. The position accounts for 0.22% of the portfolio, ranked #81.

CIM LLC first reported a position in EXEL in Q1 2019 and has held it in 7 quarters since. The position peaked at $1.59M in Q4 2025. 695 funds tracked by Wall St. Rank hold EXEL as of Q1 2026.

  • CIM LLC held 35,969 shares of Exelixis worth $1.54M as of Q1 2026.
  • CIM LLC sold 351 Exelixis shares in Q1 2026, an estimated $15.1K.
  • Exelixis made up 0.22% of CIM LLC's portfolio in Q1 2026, its #81 holding.
  • CIM LLC first reported a position in Exelixis in Q1 2019 and has held it in 7 quarters since.
  • CIM LLC's Exelixis position peaked at $1.59M in Q4 2025.
  • 695 funds tracked by Wall St. Rank held Exelixis as of Q1 2026.

Based on CIM LLC's 13F filing for Q1 2026, filed 18 May 2026.